DuPont Decomposition

Why does SHILPAMED earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

9.4% = 15.8% × 0.42 × 1.43

Latest: FY2026

Profitability

Net Margin

15.8%

5.3% →15.8%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

0.42x

0.40x →0.42x

Revenue per ₹ of assets

Leverage

Equity Multiplier

1.43x

1.58x →1.43x

Assets funded by equity vs debt

Trend Analysis

ROE improved by 6.1 pp over 5 years. Driven by net margin improving (5.3% → 15.8%).

Historical Decomposition

Last 5 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20220Cr0Cr5.3%0.401.583.3%
FY20230Cr-0Cr-3.1%0.361.63-1.8%
FY20240Cr0Cr2.8%0.371.721.8%
FY20250Cr0Cr6.1%0.391.403.3%
FY20260Cr0Cr15.8%0.421.439.4%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for SHILPAMED

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

SHILPAMED DuPont Analysis — ROE 9.4% | YieldIQ